Clinical and Translational Allergy最新文献

{"title":"Exploring the role of information and communication technologies in allergic rhinitis in specialist centers: Patient perspectives on usefulness, value, and impact on healthcare","authors":"Ivan Cherrez-Ojeda,&nbsp;Jean Bousquet,&nbsp;Zouina Sarfraz,&nbsp;Azza Sarfraz,&nbsp;Monica Rodriguez Gonzales,&nbsp;Anna Bedbrook,&nbsp;Nelson Rosario,&nbsp;Benjamin Zepeda-Ortega,&nbsp;Guillermo Guidos,&nbsp;Ulbio Alcivar Molina,&nbsp;Miguel Felix,&nbsp;Emanuel Vanegas,&nbsp;Karla Robles-Velasco,&nbsp;Luc J. Zimmermann,&nbsp;Antonio W. D. Gavilanes","doi":"10.1002/clt2.12325","DOIUrl":"https://doi.org/10.1002/clt2.12325","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Information and communication technologies (ICTs) improve patient-centered care and are routinely used in Allergic Rhinitis (AR), but patients' preferences and attitudes are unexplored. This study examines AR-related information preferences and ICT use by AR patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A survey-based cross-sectional study was carried out in Ecuador from July to September 2019 in seven centers of reference for allergic disease. Participants were 18 years or older, diagnosed with AR and had access to ICT and the Internet. Descriptive and binomial logistic regressions were performed. A value of less than 0.05 was considered statistically significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>217 patients were included. 47% (<i>n</i> = 102) used ICTs to learn about AR, of which 38.2% (<i>n</i> = 83) found it useful. Most of participants (75%, <i>n</i> = 164) did not think that ICTs reduce their need to see a doctor. Individuals with poorer quality of life were more likely to utilize ICTs to contact their doctor (OR 1.27, 95% CI 1.04–1.55), and more likely to be interested in AR-related content (OR 1.23, 95% CI 1.00–1.52). Patients with long-term AR or other allergies were less likely to use ICTs (OR 0.92 and OR 0.40 respectively). Higher education and lower quality of life may increase AR apps adoption (OR 4.82, 95% CI 1.11–21.00). Academic preparation five-fold increased ICT use for health provider communication (OR 5.29, 95% CI 1.18–23.72). Mild-persistent AR enhanced the probabilities of using ICTs to share experiences and communicate with other patients (OR 12.59, 95% CI 1.32–120.35).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study emphasizes the importance of tailoring digital resources to patient needs by considering factors such as quality of life, education, and specific subgroups within the AR patient population. Additionally, the findings suggest that while ICTs can play a valuable role in patient education and support, they should complement, rather than replace, traditional medical care for many AR patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12325","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139504581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suppressed pediatric asthma hospitalizations during the COVID-19 pandemic in Japan, from a national survey","authors":"Seigo Korematsu,&nbsp;Takao Fujisawa,&nbsp;Naruo Saito,&nbsp;Junichiro Tezuka,&nbsp;Katsushi Miura,&nbsp;Ichiro Kobayashi,&nbsp;Ippei Miyata,&nbsp;Yujiro Kosugi,&nbsp;Yuji Gohda,&nbsp;Yumi Koike,&nbsp;Ami Suda,&nbsp;Akiko Matsuo,&nbsp;Michiyo Sasaki,&nbsp;Yousuke Handa,&nbsp;Michimasa Fujiwara,&nbsp;Atsushi Ono,&nbsp;Shinya Koizumi,&nbsp;Taku Oishi,&nbsp;Takayuki Tanaka,&nbsp;Yusuke Ando,&nbsp;Naohiko Taba,&nbsp;Yuki Tsurinaga,&nbsp;Takeshi Sato,&nbsp;Rei Kanai,&nbsp;Masato Yashiro,&nbsp;Toshiyuki Takagi,&nbsp;Shinya Hida,&nbsp;Masashi Harazaki,&nbsp;Takayuki Hoshina,&nbsp;Seigo Okada,&nbsp;Motoko Yasutomi,&nbsp;Setsuko Nakata,&nbsp;Ayako Muto,&nbsp;Saori Tanabe,&nbsp;Yutaka Ueda,&nbsp;Shunji Hasegawa,&nbsp;Makoto Kameda,&nbsp;Keiko Tanaka-Taya,&nbsp;Tsuguto Fujimoto,&nbsp;Kenji Okada","doi":"10.1002/clt2.12330","DOIUrl":"https://doi.org/10.1002/clt2.12330","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acute asthma exacerbation in children is often caused by respiratory infections. In this study, a coordinated national surveillance system for acute asthma hospitalizations and causative respiratory infections was established. We herein report recent trends in pediatric acute asthma hospitalizations since the COVID-19 pandemic in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Thirty-three sentinel hospitals in Japan registered all of their hospitalized pediatric asthma patients and their causal pathogens. The changes in acute asthma hospitalization in children before and after the onset of the COVID-19 pandemic and whether or not COVID-19 caused acute asthma exacerbation were investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From fiscal years 2010–2019, the median number of acute asthma hospitalizations per year was 3524 (2462–4570), but in fiscal years 2020, 2021, and 2022, the numbers were 820, 1,001, and 1,026, respectively (the fiscal year in Japan is April to March). This decrease was observed in all age groups with the exception of the 3- to 6-year group. SARS-CoV-2 was evaluated in 2094 patients from fiscal years 2020–2022, but the first positive case was not detected until February 2022. Since then, only 36 of them have been identified with SARS-CoV-2, none of which required mechanical ventilation. Influenza, RS virus, and human metapneumovirus infections also decreased in FY 2020. In contrast, 24% of patients had not been receiving long-term control medications before admission despite the severity of bronchial asthma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>SARS-CoV-2 was hardly detected in children with acute asthma hospitalization during the COVID-19 pandemic. This result indicated that SARS-CoV-2 did not induce acute asthma exacerbation in children. Rather, infection control measures implemented against the pandemic may have consequently reduced other respiratory virus infections and thus acute asthma hospitalizations during this period. However, the fact that many hospitalized patients have not been receiving appropriate long-term control medications is a major problem that should be addressed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12330","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139494603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab improves clinical and histologic features of eosinophilic esophagitis prior to 12 weeks of treatment","authors":"Twan Sia,&nbsp;Amanda Miller,&nbsp;Leeon Bacchus,&nbsp;Jennie Young,&nbsp;Aditya P. Narayan,&nbsp;Rachel Solecki,&nbsp;Jerry Fu,&nbsp;Yuting Jiang,&nbsp;Raisa Khuda,&nbsp;Stanley Liu,&nbsp;Kathleen Love,&nbsp;Shibani Mallik,&nbsp;Amina Sara Matmatte,&nbsp;Paige McDonald,&nbsp;Tanvi Telukunta,&nbsp;Alyssa Roby,&nbsp;Saad Shami,&nbsp;Michelle Zheng,&nbsp;Madison Headen,&nbsp;John Leung","doi":"10.1002/clt2.12333","DOIUrl":"https://doi.org/10.1002/clt2.12333","url":null,"abstract":"<p>Dupilumab is a human monoclonal antibody against interleukin-4 receptor alpha subunit. Dupilumab is an approved treatment for inducing remission of eosinophilic esophagitis (EoE).<span>¹</span> EoE histologic remission with dupilumab has only been demonstrated in patients after at least 12 weeks of treatment.<span>^2-6</span> Current guidelines recommend waiting for histologic re-evaluation of EoE until after 20–24 weeks of dupilumab.<span>¹</span> It is unknown if increasing dupilumab treatment length improves its efficacy. Because histologic re-evaluation of EoE requires invasive biopsies, and inducing remission of EoE is important to prevent progressive esophageal damage, research investigating the effects of dupilumab on EoE prior to 12 weeks of treatment is warranted.</p><p>We conducted a retrospective study at a single medical clinic. The electronic medical record was searched between 2017 and 2023 using International Classifications of Disease, 10th revision code K20.0 eosinophilic esophagitis. We excluded patients who had (1) never started dupilumab; (2) no histologic confirmation of EoE defined by ≥ 15 eos/hpf; or (3) no histologic re-evaluation of EoE while on dupilumab. Histologic evaluation of EoE assessed at least 2 biopsies each of the proximal, middle, and distal esophagus. Endpoints were peak eosinophil counts (eosinophils per high-power field; eos/hpf), EoE endoscopic reference scores (EREFS), and a composite symptom score in which each symptom (dysphagia, food impaction/choking, regurgitation/vomiting, heartburn/chest pain, and abdominal pain) was graded (0 = absent, 1 = mild, 2 = moderate, and 3 = severe) and summed. This study was deemed exempt from institutional review board approval by the WCG IRB.</p><p>From the electronic medical record, 658 patients with EoE were identified, of which 534 had never initiated dupilumab, 6 did not have histologic confirmation of EoE, and 39 did not have a repeat histologic evaluation after dupilumab initiation. Therefore, 79 patients were included in this study. The median age was 27.6 years (Q1 to Q3, 21.8–36.1), 48 patients (60.8%) were male, and 12 patients (15.2%) were pediatric (Table 1). Sixty patients (75.9%) had an atopic comorbidity, including allergic rhinitis (43 patients, 54.4%), asthma (27 patients, 34.2%), atopic dermatitis (13 patients, 16.5%), and food allergies (30 patients, 38.0%).</p><p>Patients were on dupilumab for median 22.7 weeks (Q1 to Q3, 16–26.7). Dosages included 300 mg every week (71 patients, 89.9%), 300 mg every other week with a loading dose of 600 mg for atopic dermatitis (7 patients, 8.9%), and 200 mg every other week with a loading dose of 400 mg for atopic dermatitis (1 patient, 1.3%).</p><p>Of 79 patients, 12 patients (15.2%) were on dupilumab for 0–12 weeks. Patients on dupilumab for 0–12 weeks had a median composite symptom score of 5.5 (Q1 to Q3, 4–6), which significantly decreased to 0 (Q1 to Q3, 0–1; Wilcoxon matche","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12333","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139488369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory immunogenicity outcomes of peanut oral immunotherapy: Findings from the PALISADE trial","authors":"Caroline Nilsson,&nbsp;Andrea Vereda,&nbsp;Magnus P. Borres,&nbsp;Mats Andersson,&nbsp;Eva Södergren,&nbsp;Magnus Rudengren,&nbsp;Alex Smith,&nbsp;Reyna J. Simon,&nbsp;Robert Ryan,&nbsp;Montserrat Fernández-Rivas,&nbsp;Daniel Adelman,&nbsp;Brian P. Vickery","doi":"10.1002/clt2.12326","DOIUrl":"https://doi.org/10.1002/clt2.12326","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Immunoglobulin E (IgE) and immunoglobulin G4 (IgG4) to peanut and its components may influence the clinical reactivity to peanut. Allergen-specific immunotherapy is known for modifying both IgE and IgG4. Peanut oral immunotherapy may influence these serological parameters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Exploratory analyses of serological data from participants receiving peanut (<i>Arachis hypogaea</i>) allergen powder-dnfp (PTAH) and placebo in the double-blind, randomized, phase 3 PALISADE trial were conducted to evaluate potential relationships between peanut-specific and peanut component–specific (Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8, and Ara h 9) IgE and IgG4 levels and clinical outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 269 participants (PTAH, <i>n</i> = 202; placebo, <i>n</i> = 67) were analyzed. No relationship was observed between specific IgE and IgG4 levels at screening and maximum tolerated peanut protein dose during screening or response status during exit double-blind placebo-controlled food challenge (DBPCFC). In PTAH-treated participants, no relationship was observed between IgE and IgG4 levels at screening and maximum symptom severity during exit DBPCFC. Postscreening ratios (ie, postscreening/screening) in the PTAH group were significant at the end of updosing and exit visit for most components. Postscreening changes in specific IgE levels were more pronounced with PTAH versus placebo for most components.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Specific IgE and IgG4 levels at screening are not correlated with screening or exit DBPCFC results, and are not predictive of clinical response to PTAH. Peanut (<i>Arachis hypogaea</i>) allergen powder-dnfp contains the relevant and immunodominant allergens, inducing immunological changes with the treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Clinical Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov identifier: NCT02635776.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12326","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139488370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of nutritional habits, body mass index and intestinal microbiota in mastocytosis on clinical symptoms using conventional culture and next generation sequencing","authors":"Ewelina Harcęko-Zielińska,&nbsp;Marek Niedoszytko,&nbsp;Aleksandra Górska,&nbsp;Sylwia Małgorzewicz,&nbsp;Marta Gruchała-Niedoszytko,&nbsp;Marek Bronk,&nbsp;Slawomir Dąbrowski,&nbsp;Marta Chełminska,&nbsp;Ewa Jassem","doi":"10.1002/clt2.12310","DOIUrl":"https://doi.org/10.1002/clt2.12310","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Mastocytosis is a rare neoplastic disease of the bone marrow associated with the proliferation and accumulation of mast cells in various internal organs, including the gastrointestinal tract. There are few studies describing the gut microbiome of patients with mastocytosis using next generation sequencing supported using traditional culture methods. The aims of the study were, firstly, the determination of nutrition habits, composition of the intestinal microflora and BMI in mastocytosis, and secondly, analysis of mastocytosis severity and symptoms depending on the composition of the intestinal microflora.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study included 47 patients with indolent systemic mastocytosis and 18 healthy controls. All participants gave their informed consent to participate in the study. The study consisted of 3 parts: I-clinical assessment, II - examination of the intestinal microflora using the biochemical method, III - 16S rRNA sequencing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The nutrition habits and BMI of mastocytosis patients were similar to controls; however, most patients with mastocytosis had a low dietary vitamin and mineral content. As many as 94.5% of patients had too little fiber intake and mineral content. The most common cause of the abnormal stool test result with traditional culture was a titer of <i>E</i>. <i>coli</i> &lt;10⁶. The low richness of microbiota species indicated by the Simpson index was observed in mastocytosis, <i>p</i> = 0.04. There were no significant differences in the composition of the intestinal microflora depending on the type of mastocytosis; however, the tryptase level correlated with the amount of Suterella, Barnesiellaceae, Eubacterium, Odoribacter, and Anaerostipes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The nutritional habits and BMI of mastocytosis patients are similar to the general population, except for too little fiber intake and mineral content. The gastrointestinal symptoms of mastocytosis patients may be related to the low richness of microbiota species and the amount of Suterella, Barnesiellaceae, Eubacterium, Odoribacter, Anaerostipes, which correlated with tryptase levels.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12310","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139436656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacteria and viruses and clinical outcomes of asthma-bronchiectasis overlap syndrome: A cohort study","authors":"Xiao-xian Zhang,&nbsp;Jia-hui He,&nbsp;Cui-xia Pan,&nbsp;Zhen-feng He,&nbsp;Hui-min Li,&nbsp;Zhen-hong Lin,&nbsp;Xiao-fen Zhang,&nbsp;Lai-jian Cen,&nbsp;Ri-lan Zhang,&nbsp;Ming-xin Shi,&nbsp;Wei-jie Guan","doi":"10.1002/clt2.12331","DOIUrl":"https://doi.org/10.1002/clt2.12331","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Despite the high prevalence of co-existing bronchiectasis and asthma (asthma-bronchiectasis overlap syndrome [ABOS]), little is known regarding the dominant pathogens and clinical correlates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate the bacteria and viruses which differentially dominate in ABOS (including its subtypes) compared with bronchiectasis alone, and determine their relevance with bronchiectasis severity and exacerbations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a prospective observational cohort study conducted between March 2017 and August 2023. We included 81 patients with ABOS and 107 patients with bronchiectasis alone. At steady-state baseline, patients underwent comprehensive assessments and sputum collection for bacterial culture and viral detection (quantitative polymerase-chain-reaction). Patients were followed-up to record exacerbation and spirometry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients with ABOS had significantly higher symptom burden and exacerbation frequency than those with bronchiectasis alone. Despite similar pathogen spectrum, the rate of bacteria–virus co-detection increased less substantially at acute exacerbations (AE) onset than at steady-state compared with bronchiectasis alone. Pathogenic bacteria (particularly <i>Pseudomonas aeruginosa</i>) were detected fairly common (exceeding 50%) in ABOS and were associated with greater severity of bronchiectasis when stable and conferred greater exacerbation risks at follow-up. Viral but not bacterial compositions changed substantially at AE onset compared with clinical stability. Higher blood eosinophil count, moderate-to-severe bronchiectasis and non-atopy were associated with higher odds of bacterial, but not viral, detection (all <i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Detection of bacteria or virus is associated with bronchiectasis severity or clinical outcomes in ABOS. This highlights the importance of integrating sputum microbial assessment for ascertaining the dominant pathophysiology (atopy vs. infection) and longitudinal trajectory prediction in ABOS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12331","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139435122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria","authors":"Sophia Neisinger,&nbsp;Bernardo Sousa Pinto,&nbsp;Aiste Ramanauskaite,&nbsp;Jean Bousquet,&nbsp;Karsten Weller,&nbsp;Martin Metz,&nbsp;Markus Magerl,&nbsp;Emek Kocatürk,&nbsp;Ivan Cherrez-Ojeda,&nbsp;Ana M. Gimenez-Arnau,&nbsp;Claudio Alberto S. Parisi,&nbsp;Sabine Altrichter,&nbsp;Luis Felipe Ensina,&nbsp;Laurence Bouillet,&nbsp;Riccardo Asero,&nbsp;Margarida Gonçalo,&nbsp;Carole Guillet,&nbsp;Krzysztof Rutkowski,&nbsp;Jonathan A. Bernstein,&nbsp;Hannah Hardin,&nbsp;Kiran Godse,&nbsp;Zenon Brzoza,&nbsp;Jose Ignacio Larco Sousa,&nbsp;Simon Francis Thomsen,&nbsp;Martijn van Doorn,&nbsp;Michihiro Hide,&nbsp;Young-Min Ye,&nbsp;Staffan Vanderse,&nbsp;Lāsma Lapiņa,&nbsp;Jonny Peter,&nbsp;Zuotao Zhao,&nbsp;Lianyi Han,&nbsp;Iman Nasr,&nbsp;Heike Rockmann-Helmbach,&nbsp;Jennifer Astrup Sørensen,&nbsp;Rabia Öztaş Kara,&nbsp;Natalja Kurjāne,&nbsp;Andrii I. Kurchenko,&nbsp;Igor Kaidashev,&nbsp;Vladyslav Tsaryk,&nbsp;Roman Stepanenko,&nbsp;Marcus Maurer","doi":"10.1002/clt2.12328","DOIUrl":"https://doi.org/10.1002/clt2.12328","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE^®, the Chronic Urticaria Self Evaluation app, aims to address this unmet need.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>CRUSE^® was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE^® app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE^® contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>CRUSE^® was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The initial data from CRUSE^® show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12328","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139090754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics of allergic bronchopulmonary mycosis caused by Schizophyllum commune","authors":"Tsuyoshi Oguma,&nbsp;Takashi Ishiguro,&nbsp;Katsuhiko Kamei,&nbsp;Jun Tanaka,&nbsp;Junko Suzuki,&nbsp;Akira Hebisawa,&nbsp;Yasushi Obase,&nbsp;Hiroshi Mukae,&nbsp;Takae Tanosaki,&nbsp;Shiho Furusho,&nbsp;Koji Kurokawa,&nbsp;Kentaro Watai,&nbsp;Hiroto Matsuse,&nbsp;Norihiro Harada,&nbsp;Ai Nakamura,&nbsp;Takuo Shibayama,&nbsp;Rie Baba,&nbsp;Kentaro Fukunaga,&nbsp;Hisako Matsumoto,&nbsp;Hisano Ohba,&nbsp;Susumu Sakamoto,&nbsp;Shinko Suzuki,&nbsp;Shintetsu Tanaka,&nbsp;Takahiro Yamada,&nbsp;Akira Yamasaki,&nbsp;Yuma Fukutomi,&nbsp;Yoshiki Shiraishi,&nbsp;Takahito Toyotome,&nbsp;Koichi Fukunaga,&nbsp;Terufumi Shimoda,&nbsp;Satoshi Konno,&nbsp;Masami Taniguchi,&nbsp;Katsuyoshi Tomomatsu,&nbsp;Naoki Okada,&nbsp;Koichiro Asano,&nbsp;Japan ABPM Research Program","doi":"10.1002/clt2.12327","DOIUrl":"10.1002/clt2.12327","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Allergic bronchopulmonary mycosis (ABPM) is an allergic disease caused by type I and type III hypersensitivity to environmental fungi. <i>Schizophyllum commune</i>, a basidiomycete fungus, is one of the most common fungi that causes non-<i>Aspergillus</i> ABPM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Herein, we attempted to clarify the clinical characteristics of ABPM caused by <i>S. commune</i> (ABPM-Sc) compared with those of allergic bronchopulmonary aspergillosis (ABPA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with ABPM-Sc or ABPA were recruited from a nationwide survey in Japan, a multicenter cohort, and a fungal database at the Medical Mycology Research Center of Chiba University. The definition of culture-positive ABPM-Sc/ABPA is as follows: (1) fulfills five or more of the 10 diagnostic criteria for ABPM proposed by Asano et al., and (2) positive culture of <i>S. commune/Aspergillus</i> spp. in sputum, bronchial lavage fluid, or mucus plugs in the bronchi.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty patients with ABPM-Sc and 46 with ABPA were recruited. Patients with ABPM-Sc exhibited less severe asthma and presented with better pulmonary function than those with ABPA (<i>p</i> = 0.008–0.03). Central bronchiectasis was more common in ABPM-Sc than that in ABPA, whereas peripheral lung lesions, including infiltrates/ground-glass opacities or fibrotic/cystic changes, were less frequent in ABPM-Sc. <i>Aspergillus fumigatus</i>-specific immunoglobulin (Ig)E was negative in 10 patients (34%) with ABPM-Sc, who demonstrated a lower prevalence of asthma and levels of total serum IgE than those with ABPM-Sc positive for <i>A. fumigatus</i>-specific IgE or ABPA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Clinical characteristics of ABPM-Sc, especially those negative for <i>A. fumigatus</i>-specific IgE, differed from those of ABPA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12327","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139063256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the effectiveness of the peptide inhibitor homologous to the transforming growth factor β cytokine blocking the TGFβRI/TGFβRII receptor complex—pilot study","authors":"Marynowski Mateusz,&nbsp;Karbownik Michał Seweryn,&nbsp;Szemraj Janusz,&nbsp;Kuna Piotr,&nbsp;Michał Gabriel Panek","doi":"10.1002/clt2.12320","DOIUrl":"10.1002/clt2.12320","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A key player in the fibrotic process is the transforming growth factor β (TGF-β) which enhances extracellular matrix production by increasing the transcription of matrix proteins. The cytokine TGF-β first binds to the TGFβRII receptor (dimer), resulting in the recruitment of the TGFβRI receptor (dimer). The complex thus formed leads to the phosphorylation of the kinase domain of TGFβRI, which in turn results in activation of the Smad pathway. This is therefore a targeted pathway for research into the application of peptide inhibitors in blocking the TGF-β-Smad signaling pathway. The aim of this study was to design a peptide inhibitor (homologous to the cytokine TGF-β) which, after binding to the TGFβRI/TGFβRII receptor, would block the cytokine binding and thus prevent the formation of an activating complex.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Preliminary work on the design and synthesis of inhibitors for TGFβRI/TGFβRII has allowed us to identify and describe five key regions of the TGF-β—TGFβRI/TGFβRII interface. The following five peptide inhibitors were synthesized for Region 1: 1.1 ALDAAYCFR, 1.2 LDAAYCFRN, 1.3 DAAYCFRNV, 1.4 AAYCFRNVQ, 1.5 AYCFRNVQD. The expression of the SEAP reporter gene, Smad2, Smad3, Smad4, and JNK1 gene was measured using quantitative real-time polymerase chain reaction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>For Region 1 peptide inhibitors tested for TGFβRI/TGFβRII, reduced SEAP (reporter gene) expression was observed in cells of the MFB-F11 line, which suggests inhibited the formation of cytokine-receptor complexes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>For IP1_2, 1_3 and 1_5 Region 1 peptides tested for TGFβRI/TGFβRII, reduced cytokine-receptor signal by adding newly designed inhibitors. The study revealed an impact of these peptide inhibitors on the reduction of mRNA expression of Smad2, Smad3, Smad4 and JNK1 genes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12320","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139062942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerance to heated egg in egg allergy: Explanations and implications for prevention and treatment","authors":"Audrey Leau,&nbsp;Sandra Denery-Papini,&nbsp;Marie Bodinier,&nbsp;Wieneke Dijk","doi":"10.1002/clt2.12312","DOIUrl":"10.1002/clt2.12312","url":null,"abstract":"<p>Hen's egg allergy is the second most frequent food allergy found in children. Allergic symptoms can be caused by raw or heated egg, but a majority of egg-allergic children can tolerate hard-boiled or baked egg. Understanding the reasons for the tolerance towards heated egg provides clues about the molecular mechanisms involved in egg allergy, and the differential allergenicity of heated and baked egg might be exploited to prevent or treat egg allergy. In this review, we therefore discuss (i) why some patients are able to tolerate heated egg; by highlighting the structural changes of egg white (EW) proteins upon heating and their impact on immunoreactivity, as well as patient characteristics, and (ii) to what extent heated or baked EW might be useful for primary prevention strategies or oral immunotherapy. We describe that the level of immunoreactivity towards EW helps to discriminate patients tolerant or reactive to heated or baked egg. Furthermore, the use of heated or baked egg seems effective in primary prevention strategies and might limit adverse reactions. Oral immunotherapy is a promising treatment strategy, but it can sometimes cause significant adverse events. The use of heated or baked egg might limit these, but current literature is insufficient to conclude about its efficacy.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12312","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139019193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}